公开(公告)号：US11555009B2

公开(公告)日：2023-01-17

申请号：US16490186

申请日：2018-03-01

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Caiguang Yang ,  Yue Huang ,  Ze Dong ,  Tao Zhang ,  Hongjiao Xu

IPC: C07C229/58 ,  A61P35/00 ,  C07D261/08 ,  A61K31/42 ,  A61K31/196 ,  C07D231/12 ,  A61K31/415 ,  C07D213/38 ,  A61K31/4418 ,  C07D333/20 ,  A61K31/381 ,  C07D239/26 ,  A61K31/505 ,  C07D333/40 ,  C07D239/42 ,  C07D211/70 ,  C07D209/14 ,  A61K31/404 ,  C07D233/64 ,  A61K31/4164 ,  C07D257/04 ,  A61K31/41 ,  C07D407/12 ,  A61K31/422 ,  A61K31/4245 ,  C07D401/12 ,  A61K31/4439 ,  A61K31/5355 ,  C07C227/16

Abstract: The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.